Related Experiment Video
Updated: May 28, 2026
11:00
Microfluidic Chip for Axonal Injury Models Construction and Enabling Multi-Omics Analysis
Published on: October 14, 2025
A Microfluidic Framework for Neuroprotective Compound Triage Across Ischemia and Neurodegeneration
Julia Anchimowicz1, Slawomir Jakiela1
1Department of Physics and Biophysics, Institute of Biology, Warsaw University of Life Sciences, 02-787 Warsaw, Poland.
Molecules (Basel, Switzerland)
|May 27, 2026
Summary
Microfluidic systems help neuroprotection research by identifying failing compounds early. This framework uses microfluidics for prescreening, blood-brain barrier filtering, and validation, preventing costly late-stage failures.
Area of Science:
- Neuroscience
- Pharmacology
- Biotechnology
Background:
- Microfluidic systems are gaining traction in neuroprotection research.
- Identifying reasons for candidate compound failure early is crucial to optimize drug discovery pipelines.
Purpose of the Study:
- To review CNS-relevant microfluidic studies within a triage logic framework.
- To evaluate microfluidics' role in prescreening, filtering, and validating neuroprotective compounds.
Main Methods:
- Examined microfluidic studies focusing on the central nervous system (CNS).
- Applied a triage logic linking chemistry-aware prescreening, blood-brain barrier/neurovascular unit (BBB/NVU) filtering, and validation in neuronal ischemia/reperfusion models.
- Considered non-CNS organ-on-a-chip and analytical microfluidics as engineering analogies.
Main Results:
- Blood-brain barrier/neurovascular unit (BBB/NVU) chips excel as exposure- and safety-aware filters.
- Compartmentalized neuronal oxygen-glucose deprivation platforms serve as timing-sensitive validation tools.
- Droplet microfluidics aids in upstream dose mapping, aggregation assays, and counterscreens.
Conclusions:
- Microfluidics provides a framework for early identification of compound liabilities (transport, barrier, timing, assay issues).
- This approach optimizes neuroprotective discovery by preventing failures in costly downstream models.
- Microfluidics is best used as an operational framework, not a universal disease model.
